2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbs
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Melanoma
Conditions
Melanoma
Trial Timeline
Jun 1, 2010 → Apr 1, 2014
NCT ID
NCT01308294About 2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbs
2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbs is a phase 1/2 stage product being developed by Immutep for Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01308294. Target conditions include Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01308294 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Binimetinib Oral Tablet | Biotrial | Phase 1 | 25 |
| Tasisulam-sodium + Paclitaxel | Eli Lilly | Phase 3 | 77 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT01 + [68Ga]VMT02 | Perspective Therapeutics | Phase 1 | 25 |
| FYB206 + Keytruda | Formycon AG | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Pre-clinical | 23 |
| PLX3397 + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | 41 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DS-8273a + Nivolumab | Daiichi Sankyo | Phase 1 | 33 |
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| enfortumab vedotin + pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| YM155 | Astellas Pharma | Phase 2 | 52 |
| YM155 + Docetaxel | Astellas Pharma | Phase 2 | 52 |
| Denileukin diftitox | Eisai | Phase 2 | 52 |
| E7080 | Eisai | Phase 1 | 33 |
| lenvatinib + pembrolizumab | Eisai | Phase 2 | 52 |
| MORAb-004 (monoclonal antibody) | Eisai | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Lenvatinib + Dacarbazine | Eisai | Phase 1/2 | 41 |
Other Products from Immutep
eftilagimod alpha + PaclitaxelPhase 2/3
57
Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.vPhase 2
44
Pembrolizumab, Eftilagimod alfaPhase 2
44
IMP321 (eftilagimod alpha) + Placebo + PaclitaxelPhase 2
44
Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321Phase 1/2
33